Emerging insights into mechanisms of trastuzumab resistance in HER2-positive cancers.
HER2
Resistance
Trastuzumab
Journal
International immunopharmacology
ISSN: 1878-1705
Titre abrégé: Int Immunopharmacol
Pays: Netherlands
ID NLM: 100965259
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
06
05
2023
revised:
19
06
2023
accepted:
02
07
2023
medline:
25
8
2023
pubmed:
13
7
2023
entrez:
12
7
2023
Statut:
ppublish
Résumé
HER2 is an established therapeutic target in breast, gastric, and gastroesophageal junction carcinomas with HER2 overexpression or genomic alterations. The humanized monoclonal antibody trastuzumab targeting HER2 has substantially improved the clinical outcomes of HER2-positive patients, yet the inevitable intrinsic or acquired resistance to trastuzumab limits its clinical benefit, necessitating the elucidation of resistance mechanisms to develop alternate therapeutic strategies. This review presents an overview of trastuzumab resistance mechanisms involving signaling pathways, cellular metabolism, cell plasticity, and tumor microenvironment, particularly discussing the prospects of developing rational combinations to improve patient outcomes.
Identifiants
pubmed: 37437432
pii: S1567-5769(23)00927-X
doi: 10.1016/j.intimp.2023.110602
pii:
doi:
Substances chimiques
Trastuzumab
P188ANX8CK
Receptor, ErbB-2
EC 2.7.10.1
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
110602Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.